Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos and Tarsus...
A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders. Trial...
DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
...or excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older. The GABA B receptor... ...lisocabtagene maraleucel, (JCAR017)
Aurinia Pharmaceuticals Inc.
Averitas Pharma Inc.
Vertex Pharmaceuticals Inc.
Bristol Myers Squibb Co.
GABA B receptor
Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
Ovid’s gaboxadol meets in Phase II for Fragile X Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to treat...
...or excessive daytime sleepiness (EDS) in narcolepsy patients 7 years of age and older. The GABA B receptor... ...Pharmaceuticals Inc.
Otsuka Pharmaceutical Co. Ltd.
Jazz Pharmaceuticals plc
Forge Therapeutics Inc.
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR)
GABA B receptor...